| CDS Tool Information - Medications for Lowering Glucose, Summary of Characteristics | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intended Purpose(s) | NA | ||||||||||||||||||||||||||||||
| Indicated in patients with | Diabetes | ||||||||||||||||||||||||||||||
| Indicated in ff. interventions | NA | ||||||||||||||||||||||||||||||
| Predicted Outcomes | NA | ||||||||||||||||||||||||||||||
| Prediction Period | NA | ||||||||||||||||||||||||||||||
| Caution(s) | NA | ||||||||||||||||||||||||||||||
| Mathematical Formula |
Medications for lowering glucose, summary of characteristics
CV, cardiovascular; CVOT, cardiovascular outcomes trial; DKA, diabetic ketoacidosis; DKD, diabetic kidney disease; DPP-4, dipeptidyl peptidase 4; eGFR, estimated glomerular filtration rate; GI, gastrointestinal; GIP, glucose-dependent insulinotropic polypeptide; GLP-1 RA, glucagon-like peptide 1 receptor agonist; HF, heart failure; NASH, nonalcoholic steatohepatitis; MACE, major adverse cardiovascular events; SGLT2, sodium–glucose cotransporter 2; SQ, subcutaneous; T2DM, type 2 diabetes mellitus. *For agent-specific dosing recommendations, please refer to manufacturers’ prescribing information. 1Tsapas et al. (104). 2Tsapas et al. (152). Adapted from Davies et al. (84). | ||||||||||||||||||||||||||||||
| Additional Explanations |
NA | ||||||||||||||||||||||||||||||
| Interpretation |
NA | ||||||||||||||||||||||||||||||
| Recommendations |
NA | ||||||||||||||||||||||||||||||
| Original Reference |
American Diabetes Association Professional Practice Committee, "Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes-2024", Diabetes Care, vol. 47, Suppl. 1, pp. S158–S178. https://doi.org/10.2337/dc24-S009 | ||||||||||||||||||||||||||||||
| Validation Reference(s) |
NA | ||||||||||||||||||||||||||||||
| Other Reference(s) |
NA | ||||||||||||||||||||||||||||||
| Abbreviation Text |
| ||||||||||||||||||||||||||||||
| Footnote Text |
<sup>*</sup>For agent-specific dosing recommendations, please refer to manufacturers’ prescribing information. <sup>1</sup>Tsapas et al. (104). <sup>2</sup>Tsapas et al. (152). Adapted from Davies et al. (84). | ||||||||||||||||||||||||||||||
